Kathryn E. Haley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kathryn E. Haley has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Alessandra Di Grande
26 shared publicationsBrian Mooney
26 shared publications- Bruce Moran
St Vincent’s University Hospital, D04 T6F4 Dublin, Ireland
25 shared publications Catríona M. Dowling
25 shared publications- Damir Varešlija
Royal College of Surgeons in Ireland
25 shared publications Finbarr Tarrant
25 shared publications
Latest Publications
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S6 from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Figure S6. BRD3 and BRD4 are associated with disease-specific survival in METABRIC cohort.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Figure S6. BRD3 and BRD4 are associated with disease-specific survival in METABRIC cohort.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Updated FigS3 to include wnt11 knockdown data
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Updated FigS3 to include wnt11 knockdown data
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Supplementary data figure legends updated to include wnt11 knockdown data in FigS3 (untracked)
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Supplementary data figure legends updated to include wnt11 knockdown data in FigS3 (untracked)
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Figure S5: FGFR1 and JQ1 combination in 3D cultures of CAMA1 and IDC cell lines
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Figure S5: FGFR1 and JQ1 combination in 3D cultures of CAMA1 and IDC cell lines
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figures S4 from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Figure S4. Induction of FGFR1 following JQ1 treatment in ILC and IDC cell lines.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigures S4 from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Figure S4. Induction of FGFR1 following JQ1 treatment in ILC and IDC cell lines.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Table S3: Cox regression analysis on RATHER RNA-seq data
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Table S3: Cox regression analysis on RATHER RNA-seq data
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Updated FigS3 to include wnt11 knockdown data
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Updated FigS3 to include wnt11 knockdown data
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Supplementary data figure legends updated to include wnt11 knockdown data in FigS3 (untracked)
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Supplementary data figure legends updated to include wnt11 knockdown data in FigS3 (untracked)